Financing resistance | Why new investors are urgently needed and where they come from Moderator: Peter Beyer – Senior Advisor Department of Essential Medicines…
Regulatory perspective | Current status and the post-COVID outlook for antibiotic clinical trials & approvals Moderator: John Rex, Chief Medical Officer, F2G Ltd. Speakers:…
Global markets | Why we need to think global to tackle AMR Moderator: Marc Lemonnier – Founding CEO, Antabio SAS Speakers: Heiman Wertheim –…
Diagnostics | Novel solutions to solve the reimbursement challenge Moderator: Till Bachmann – Deputy Head of Infection Medicine and Personal chair of Molecular Diagnostics…
AMR pull incentives | Will COVID-19 speed up or slow down implementation? Moderator: Kathy Talkington, Director Health Programs, Pew Charitable Trust Speakers: Suzanne Edwards…
Business models in AMR | How to develop strategic decisions in a challenging and global AMR market Sponsored by: Moderator: Gökhan Batur – CEO,…
Business models | The AMR company of the future – Which route to success Sponsored by: Moderator: Erin Duffy – Chief of Research &…
Closing session The future of AMR: How a new post-COVID-19 policy roadmap could look like Moderator: Marc Gitzinger – CEO & Vice-President, BioVersys AG,…